New cocktail targets genetic weakness in advanced breast cancer

NCT ID NCT07618390

Not yet recruiting Disease control Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of three drugs—inavolisib, ribociclib, and fulvestrant—in 160 Chinese women with a specific genetic mutation (PIK3CA) in hormone receptor-positive, HER2-negative advanced breast cancer that has stopped responding to endocrine therapy. The goal is to see if the combination can delay cancer progression. Participants will take daily pills and receive injections until the disease worsens or side effects become unacceptable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inavolisib, ribociclib, and fulvestrant
What this could lead to: If successful, this combination could offer a new first-line treatment option for Chinese patients with a specific genetic subtype of advanced breast cancer.
What could go wrong: This is an early-phase, single-arm study with no comparison group, so results may not confirm real benefit. Side effects from the three-drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.